Investor Presentaiton
Investor presentation
ADA 2019
Slide 16
The SOUL trial will provide robust evidence on the cardiovascular
benefits of oral semaglutide in people with type 2 diabetes
Randomised:
9,642 patients
with type 2
diabetes
SOUL trial design
Oral semaglutide 14 mg + standard
of care
Placebo + standard of care
Event-driven
SOUL trial key inclusion criteria
Key endpoints
Primary:
·
Cardiovascular death, non-fatal myocardial infarction or
non-fatal stroke (MACE)
Secondary confirmatory:
5-component composite CKD endpoints
Cardiovascular Death
à composite peripheral artery endpoint
Standard of care allows all glucose lowering drugs except GLP-1s; CKD: chronic kidney disease
People with type 2 diabetes from 34 countries with
primarily moderate Chronic Kidney Disease
•
HbA1c ≤10%
Age ≥50 years
At least 1 of the following: Coronary heart disease,
Cerebrovascular disease, Symptomatic peripheral
arterial disease, Chronic kidney disease
Trial initiation: Q2 2019
novo nordiskView entire presentation